Columbus, Ohio
CNS clinical trials in Columbus, OH
54 CNS studies are recruiting participants at sites in Columbus as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Columbus at a glance
- 54 studies are recruiting at a site in Columbus.
- By phase: Phase 1 (3), Phase 1/2 (4), Phase 2 (11), Phase 2/3 (1), Phase 3 (18), Phase 4 (2), No phase (9), Observational (6). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (37), university, hospital or other (16), government (1).
- By research area: Depression (19), Parkinson's Disease (12), Multiple Sclerosis (10), Migraine (6), Epilepsy (4), ADHD (2), Schizophrenia (1).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Columbus
Basic details from each study's public record (the 30 most recently updated of 54). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- The Ohio State University, Department of Psychiatry
- Registry record
- NCT07002034 · updated
Restoring Emotional Needs With Exogenous Ketones for Women With Postpartum Depression
- No phase
- Ages 18 to 45
- Female participants
- Sponsor
- Ohio State University
- Study site
- The Ohio State University
- Registry record
- NCT07919392 · updated
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- LivaNova
- Study site
- The Ohio State University
- Registry record
- NCT03887715 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Mount Carmel East Hospital · Ohio State University Comprehensive Cancer Center
- Registry record
- NCT06748222 · updated
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- The Ohio State University
- Registry record
- NCT05850689 · updated
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- The Ohio State University
- Registry record
- NCT06559306 · updated
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Ohio State University
- Registry record
- NCT07716098 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Columbus, OH on ClinicalTrials.gov.
Schizophrenia studies recruiting in Columbus
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Ohio State University
- Registry record
- NCT06585787 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Columbus, OH on ClinicalTrials.gov.
ADHD studies recruiting in Columbus
The Myelin Disorders Biorepository Project
- Observational
- All ages
- All sexes
- Sponsor
- Children's Hospital of Philadelphia
- Study site
- Nationwide Children's Hospital
- Registry record
- NCT03047369 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Columbus, OH on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Columbus
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Boston Scientific Corporation
- Study site
- Ohio State University
- Registry record
- NCT02071134 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
- Registry record
- NCT06952504 · updated
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6002)
- Registry record
- NCT07216703 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- The Ohio State University
- Registry record
- NCT06680830 · updated
A Study of Buntanetap in Participants With PD
- Phase 2/3
- Ages 40 to 85
- All sexes
- Sponsor
- Annovis Bio Inc.
- Study site
- The Ohio State University Wexner Medical Center
- Registry record
- NCT07284784 · updated
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015)
- Registry record
- NCT04165070 · updated
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Ohio State University Comprehensive Cancer Center ( Site 0015)
- Registry record
- NCT04165798 · updated
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
- Phase 2
- Ages 30 to 80
- All sexes
- Sponsor
- Appello Pharmaceuticals, Inc.
- Study site
- The Ohio State University Wexner Medical Center (site #207)
- Registry record
- NCT07432958 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Columbus, OH on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Columbus
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT03816345 · updated
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Zenas BioPharma (USA), LLC
- Study sites
- The Boster Center for Multiple Sclerosis · The Ohio State University Wexner Medical Center (OSUWMC)
- Registry record
- NCT07299019 · updated
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Zenas BioPharma (USA), LLC
- Study sites
- The Boster Center for Multiple Sclerosis · The Ohio State University Wexner Medical Center (OSUWMC)
- Registry record
- NCT07067463 · updated
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06433752 · updated
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Sundance Biosciences, Inc.
- Study site
- Local Institution - Site 104
- Registry record
- NCT07840326 · updated
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06680037 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Columbus, OH on ClinicalTrials.gov.
Epilepsy studies recruiting in Columbus
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study sites
- OhioHealth Riverside Methodist Hospital · The Ohio State University
- Registry record
- NCT05667142 · updated
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- OhioHealth
- Registry record
- NCT05716100 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Columbus, OH on ClinicalTrials.gov.
Migraine studies recruiting in Columbus
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Ohio State University Wexner Medical Center
- Registry record
- NCT06972056 · updated
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Centricity Research; Columbus, Ohio
- Registry record
- NCT07816367 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Hometown Research
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Hometown Research
- Registry record
- NCT07674654 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Columbus, OH on ClinicalTrials.gov.
Ask about studies near Columbus
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
175 studies recruiting across 37 cities.
Cincinnati
72 studies recruiting.
Cleveland
55 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections